Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00085787 | A Study of ARRY-142886 in Patients With Advanced Cancer | PHASE1 | COMPLETED | 57 | — | — | Jun 1, 2004 | Feb 1, 2007 | Oct 14, 2020 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| ARRY-142886 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-142886, MEK inhibitor; oral | DRUG | Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule |
Key Inclusion Criteria (Part 2): * Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study. * Eastern Cooperat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |